These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27629543)

  • 1. CKLF-Like MARVEL Transmembrane Domain-Containing Member 3 (CMTM3) Inhibits the Proliferation and Tumorigenisis in Hepatocellular Carcinoma Cells.
    Li W; Zhang S
    Oncol Res; 2017 Jan; 25(2):285-293. PubMed ID: 27629543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma.
    Zhang H; Zhang J; Nan X; Li X; Qu J; Hong Y; Sun L; Chen Y; Li T
    Tumour Biol; 2015 Sep; 36(10):7849-58. PubMed ID: 25946973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-135b-5p promotes gastric cancer progression by targeting CMTM3.
    Lu M; Huang Y; Sun W; Li P; Li L; Li L
    Int J Oncol; 2018 Feb; 52(2):589-598. PubMed ID: 29345297
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Li D; Huang S; Luo C; Xu Y; Fu S; Liu K; Wu J
    Curr Oncol; 2023 Feb; 30(3):2653-2672. PubMed ID: 36975415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research Advances in CKLFSF-like MARVEL Transmembrane Domain Containing Member 3.
    Hu FZ; Sheng ZZ; Qin CP; Xu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2016 Jun; 38(3):360-3. PubMed ID: 27469927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of CMTM7 inhibits cell growth and migration in liver cancer.
    Huang ZM; Li PL; Yang P; Hou XD; Yang YL; Xu X; Xu F
    Kaohsiung J Med Sci; 2019 Jun; 35(6):332-340. PubMed ID: 30903681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CMTM3 is reduced in prostate cancer and inhibits migration, invasion and growth of LNCaP cells.
    Hu F; Yuan W; Wang X; Sheng Z; Yuan Y; Qin C; He C; Xu T
    Clin Transl Oncol; 2015 Aug; 17(8):632-9. PubMed ID: 25990505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.
    Yuan W; Li T; Mo X; Wang X; Liu B; Wang W; Su Y; Xu L; Han W
    Oncotarget; 2016 May; 7(20):29507-19. PubMed ID: 27121055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMTM3 (CKLF-Like Marvel Transmembrane Domain 3) Mediates Angiogenesis by Regulating Cell Surface Availability of VE-Cadherin in Endothelial Adherens Junctions.
    Chrifi I; Louzao-Martinez L; Brandt M; van Dijk CGM; Burgisser P; Zhu C; Kros JM; Duncker DJ; Cheng C
    Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1098-1114. PubMed ID: 28428220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway.
    Yuan W; Wei F; Ouyang H; Ren X; Hang J; Mo X; Liu Z
    Cancer Cell Int; 2021 Sep; 21(1):510. PubMed ID: 34560882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CKLF1 Enhances Inflammation-Mediated Carcinogenesis and Prevents Doxorubicin-Induced Apoptosis via IL6/STAT3 Signaling in HCC.
    Liu Y; Liu L; Zhou Y; Zhou P; Yan Q; Chen X; Ding S; Zhu F
    Clin Cancer Res; 2019 Jul; 25(13):4141-4154. PubMed ID: 30918019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
    Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
    J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM3 decreases EGFR expression and EGF-mediated tumorigenicity by promoting Rab5 activity in gastric cancer.
    Yuan W; Liu B; Wang X; Li T; Xue H; Mo X; Yang S; Ding S; Han W
    Cancer Lett; 2017 Feb; 386():77-86. PubMed ID: 27867015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of miR-10b-3p promotes the progression of hepatocellular carcinoma cells via targeting CMTM5.
    Guan L; Ji D; Liang N; Li S; Sun B
    J Cell Mol Med; 2018 Jul; 22(7):3434-3441. PubMed ID: 29691981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
    Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer.
    Su Y; Lin Y; Zhang L; Liu B; Yuan W; Mo X; Wang X; Li H; Xing X; Cheng X; Dong B; Hu Y; Du H; Zhu Y; Ding N; Li J; Liu W; Ma Y; Qiu X; Ji J; Han W
    Cancer Sci; 2014 Jan; 105(1):26-34. PubMed ID: 24131472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Knockdown of CMTM3 promotes migration and invasion of PC3 cell in vitro].
    Hu FZ; Yuan WQ; Wang XL; Qin CP; Sheng ZZ; DU YQ; Yin HQ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):594-597. PubMed ID: 29263495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1.
    Huang XP; Hou J; Shen XY; Huang CY; Zhang XH; Xie YA; Luo XL
    FEBS J; 2015 Feb; 282(3):579-94. PubMed ID: 25475121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation.
    Shen E; Piao M; Li Y; Wu Y; Li S; Lee SH; Jin L; Lee KY
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.